Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
Filed with ASX · · 3 pages · English
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Recce Receives AUD $11.17m R&D Advance
- Safety Committee Approves Expansion of Ph I/II DFI Trial
- RCE Establishes Strategic Partnership in South-East Asia
- Positive Ph I/II DFI Efficacy Data to Support Site Expansion
- Murdoch Children's R327 Efficacy UTI in-vivo
Later from Recce Pharmaceuticals
- Patent Granted in Israel for RECCE Anti-Infectives
- Recce Pharmaceuticals - Business Update
- Recce Completes 5,000 R327 Doses Per Week under GMP
- Safety Committee Approves High Dose of 4,000mg
- China Patent Granted for RECCE Anti-Infectives
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals